MedTrace Logo

Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) in Cancer Patients

NCT03100071 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2021-08-03

No results posted yet for this study

Summary

Cancer patients with Central Venous Catheter (CVC) Associated Deep Vein Thrombosis (DVT) will be treated with Low Molecular Weight Heparin (LMWH) and apixaban. Study duration is 12 weeks.

Conditions

  • Cancer Patients
  • Central Venous Catheter Thrombosis
  • Upper Extremity Thrombosis

Interventions

DRUG

Apixaban

Patients will be treated with Low Molecular Weight Heparin (LMWH) for 1 week and then with apixaban 5 milligram (mg) twice daily for 11 weeks.

Sponsors & Collaborators

  • Ottawa Hospital Research Institute

    collaborator OTHER

  • Jewish General Hospital

    collaborator OTHER

  • Michael Kovacs

    lead OTHER

Principal Investigators

  • Michael Kovacs · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-15
Primary Completion
2021-08-31
Completion
2021-08-31
FDA Drug
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03100071 on ClinicalTrials.gov